Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals is viewed favorably because its core franchises remain durable, especially Dupixent’s proven real-world efficacy, long-term safety, and multiple indication-expansion opportunities, while Eylea HD adoption and the expected Eylea HD pre-filled syringe approval add near-term upside. The company also benefits from a broad pipeline spanning oncology, inflammation, obesity, allergy, and genetic medicine, with collaborations that diversify risk and amplify development expertise, and its market entrenchment should help Dupixent defend share against competition. Financially, the thesis is supported by a $3.4B buyback, and the company’s responsible-pricing reputation and sustainability focus may reinforce investor confidence as negotiations with Sanofi and other catalysts unfold.

Regeneron Pharmaceuticals is facing a negative fundamental setup because its Eylea franchise is exposed to biosimilar erosion, additional entrants, and new biologic competition, while the company itself expects franchise sales to erode over time despite conversion to high-dose aflibercept. Dupixent adds another layer of uncertainty through intensifying competition, possible patent and exclusivity risks, and IRA pricing pressure, while pipeline disappointments have already hurt sentiment: fianlimab missed its primary endpoint in 1L metastatic melanoma with an HR of 0.845 and p=0.0627, reducing estimated peak sales to $72M from $521M. With clinical and regulatory risk still high across oncology and other programs, the stock may continue to trade at a discount as near-term growth hinges on factors that do not appear imminent.